This may also be the reason for CCL2 and CXCL10 increase in high STAT1 patients and why CCL2 and CXCL10 are not as significantly lower in SLE patients undergoing therapy in the high STAT1 patients compared to the low STAT1 patients. This evidence concerns the gene STAT1 and systemic lupus erythematosus.